|
|
Impact of cholangitis on survival of patients with malignant biliary obstruction treated with percutaneous transhepatic biliary drainage |
|---|---|
| Author: | Niemelä, Jarmo1; Kallio, Raija2; Ohtonen, Pasi3; |
| Organizations: |
1Department of Surgery and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland 2Department of Oncology, Oulu University Hospital, Oulu, Finland 3Divisions of Operative Care and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
4Department of Infection Control, Oulu University Hospital, Oulu, Finland
|
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 1.2 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe20230927137562 |
| Language: | English |
| Published: |
Springer Nature,
2023
|
| Publish Date: | 2023-09-27 |
| Description: |
AbstractPurpose: To evaluate the impact of cholangitis on survival of patients with gastrointestinal cancer and malignant biliary obstruction treated with percutaneous transhepatic biliary drainage (PTBD). Methods: A retrospective registry study was performed at a tertiary center from 2000 to 2016 in Northern Finland. Results: The study included 588 patients, 258 (43.9%) patients with pancreatic cancer, 222 (37.7%) with biliary tract cancer, and 108 (18.4%) with metastasis from gastrointestinal cancers. Patient mean age was 70 years, range 26 − 93 years. There were 288 [49.0%] women. The 30-day mortality rate was 30.8% for 156 patients with cholangitis before PTBD, 19.5% for 215 patients with cholangitis after PTBD and 25.8% for 217 patients without cholangitis (P = 0.039). The median survival was 1.8 months for patients with cholangitis before PTBD, 3.0 months for patients with cholangitis after PTBD, and 3.2 months for patients without cholangitis (P = 0.002). The hazard ratio (HR) for 1-year mortality for patients with cholangitis before PTBD was 1.3 (95% CI 1.06 − 1.67, P = 0.015) compared to patients with cholangitis after PTBD. After successful PTBD, 54 out of 291 patients received chemotherapy; the median survival was 5.2 months with cholangitis before PTBD, 9.4 months with cholangitis after PTBD and 15.3 months without cholangitis. Conclusion: In gastrointestinal cancers with malignant biliary obstruction, survival is poorer if cholangitis occurs before PTBD compared to cholangitis after PTBD. An oncologist’s consultation is essential for assessing the possibility of chemotherapy in successfully treated PTBD patients, because of the notable survival benefit. see all
|
| Series: |
BMC gastroenterology |
| ISSN: | 1471-230X |
| ISSN-E: | 1471-230X |
| ISSN-L: | 1471-230X |
| Volume: | 23 |
| Issue: | 1 |
| Article number: | 91 |
| DOI: | 10.1186/s12876-023-02704-8 |
| OADOI: | https://oadoi.org/10.1186/s12876-023-02704-8 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3122 Cancers |
| Subjects: | |
| Funding: |
Open Access funding provided by University of Oulu including Oulu University Hospital. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors. |
| Copyright information: |
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
|
https://creativecommons.org/licenses/by/4.0/ |